Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, and Saskatchewan Health Authority, Saskatoon, Canada.
Department of Pathology and Laboratory Medicine, Royal University Hospital, 103 Hospital Drive, Saskatoon, SK, S7N 0W8, Canada.
Endocr Pathol. 2018 Jun;29(2):199-205. doi: 10.1007/s12022-018-9529-4.
There are two aspects of immunohistochemistry (IHC) that are relevant to practicing pathologist: (1) understanding of IHC biomarker panels that are suitable for diagnostic, prognostic and predictive testing, and (2) understanding of IHC quality assurance (QA), which makes sure that the tests in these panels work as they should. The two aspects are closely linked together and call for collaborative approach between pathologists and IHC laboratory technologists as both need to be involved in developing and maintaining IHC biomarkers that are "fit-for-purpose". This article reviews the most current IHC QA concepts that are imminently material to practicing pathologists with emphasis on challenges that are specific to endocrine pathology.
免疫组织化学（IHC）有两个方面与病理医生的实践相关：（1）了解适用于诊断、预后和预测检测的 IHC 生物标志物组合；（2）了解免疫组织化学质量保证（QA），以确保这些组合中的测试按预期进行。这两个方面紧密相连，需要病理医生和 IHC 实验室技术人员之间的协作方法，因为两者都需要参与开发和维护“适用目的”的 IHC 生物标志物。本文回顾了当前对病理医生最具意义的免疫组织化学 QA 概念，重点介绍了内分泌病理学特有的挑战。
